Skip to content
Fencer Intel
high 8.8

CVE-2025-67645 json

OpenEMR Vulnerable to Broken Access Control in Profile Edit Endpoint

published 9mo ago modified 4mo ago also EUVD-2025-206415

cvss
8.8
version 3.1, CNA
cisa kev
Not listed
not in CISA's catalog
epss
0.4%
EPSS 0.4% chance of exploitation in 30 days, percentile 34%
public exploits
0
none known

Summary

OpenEMR is a free and open source electronic health records and medical practice management application. Versions prior to 7.0.4 have a broken access control in the Profile Edit endpoint. An authenticated normal user can modify the request parameters (pubpid / pid) to reference another user’s record; the server accepts the modified IDs and applies the changes to that other user’s profile. This allows one user to alter another user’s profile data (name, contact info, etc.), and could enable account takeover. Version 7.0.4 fixes the issue.

Patch / fix

  • open-emr openemr 7.0.4

Is CVE-2025-67645 in your stack? Fencer shows which of your repositories are affected as soon as an advisory lands, and opens the fix as a pull request.

Check with Fencer

CISA SSVC

Exploitation
Proof of concept is public
Automatable
no
Technical impact
total
Assessed
9mo ago

Exploit prediction

0.40% chance of exploitation in the next 30 days, higher than 34% of all scored CVEs (FIRST EPSS, 2026-11-09).

Exploits and checks

  • github.com https://github.com/openemr/openemr/security/advisories/GHSA-vjmv-cf46-gffv referenced PoC, tagged "exploit" by a source, unverified

CVSS scores

assigned by version score vector
CNA 3.1 8.8 CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Affected products

  • openemr openemr

Classification

Weakness

References

Sources

Fencer Intel keeps one entry per vulnerability: the CVE id wins, then GHSA, and records that alias each other are merged, except that two CVEs always keep separate entries. The same data is available as JSON.

CPEs and fixed versions use Anchore's correction of NVD's data: Added CPE configurations because not yet analyzed by NVD.